The non-traumatic intranasal way of insulin delivery was successfully applied in clinical trials to treat patients with Alzheimer’s disease, Parkinson’s disease and other neurodegenerative disorders [9,10,11]. The gene discussed is INS; the disease is early-onset autosomal dominant Alzheimer disease.